Cefepime Hcl & Tazobactam For Inj. 281.25 Mg/562.5 Mg/1.125 Gm./2.25 Gm. Cephalosporins (Dry Powder Injection) Vial

What is Cefepime Hcl & Tazobactam For Inj. 281.25 Mg/562.5 Mg/1.125 Gm./2.25 Gm. Cephalosporins (Dry Powder Injection) Vial?

Cefepime HCl and Tazobactam for Injection is a combination antibacterial product presented as a dry powder injection. Cefepime is a fourth-generation cephalosporin antibiotic, while tazobactam is a beta-lactamase inhibitor. The combination is intended for selected bacterial infections when supported by the approved product information and susceptibility data. The precise indications and individual ingredient strengths must be confirmed against the product specification.

Uses / Indications

The clinical uses of Cefepime HCl and Tazobactam Injection depend on the approved formulation, the susceptibility of the causative organism and applicable treatment guidelines.

Potential clinical considerations may include:

• Selected bacterial infections requiring injectable antibacterial treatment.

• Certain infections caused by susceptible bacteria that produce beta-lactamase enzymes inhibited by tazobactam.

• Other infections only where the combination’s approved indications and antibacterial activity support its use.

The exact indications for this specific combination should be verified against its approved prescribing information. Do not assume that the product is effective against all resistant bacteria or suitable for every serious infection. It does not treat viral infections such as influenza or the common cold.

6. Benefits

• Combines cefepime, a fourth-generation cephalosporin antibiotic, with tazobactam, a beta-lactamase inhibitor.

• Supplied in a dry powder injection presentation for preparation according to approved instructions.

• Offers a combination formulation for clinical use where supported by the product’s approved indications.

• Allows selection of a suitable presentation according to verified strength and supply requirements.

• Kelar Pharmachem India supports pharmaceutical sourcing and export requirements, subject to product availability and destination-market requirements.

Clinical suitability depends on the precise formulation, bacterial susceptibility, patient factors and professional assessment.

7. Side Effects

The adverse effects of this combination depend on the individual ingredients, their doses and the specific approved formulation.

Common Side Effects

Potential effects associated with cefepime-containing treatment may include:

• Diarrhoea.

• Nausea or vomiting.

• Skin rash.

• Headache.

• Injection-site reactions.

The frequency of these effects for the exact combination has not been established from the information supplied.

Less Common or Serious Side Effects

• Serious allergic reactions, including anaphylaxis.

• Severe or persistent antibiotic-associated diarrhoea, including possible Clostridioides difficile infection.

• Changes in blood cell counts.

• Abnormal liver function tests.

• Kidney-related complications in susceptible patients.

• Neurological toxicity, including confusion, altered consciousness, myoclonus or seizures, particularly when cefepime accumulates in patients with renal impairment.

Refer to the approved prescribing information for the complete safety profile of this specific formulation. Suspected serious reactions require prompt medical assessment.

8. How Does It Work?

Cefepime belongs to the beta-lactam group of antibiotics. It acts by binding to bacterial penicillin-binding proteins and interfering with bacterial cell-wall synthesis, which can lead to the death of susceptible bacteria.

Tazobactam inhibits certain beta-lactamase enzymes that can inactivate some beta-lactam antibiotics. This inhibition may help protect the accompanying antibiotic against susceptible enzyme-mediated resistance mechanisms.

The combination does not overcome all forms of bacterial resistance. Its clinical activity depends on the formulation, the organisms involved and their susceptibility.

9. Dosage Guidelines

Dosage depends on the exact ingredient quantities, infection being treated, infection severity, patient age and weight where relevant, renal function and the approved prescribing information.

• Confirm the individual quantities of cefepime and tazobactam represented by each stated strength.

• Do not infer the ingredient ratio from the listed strengths alone.

• Dosage adjustment may be required in patients with renal impairment.

• Reconstitution, dilution and administration must follow the approved instructions for the exact product.

• Preparation and administration must be carried out by appropriately qualified healthcare professionals.

The exact dose and treatment duration should follow the approved product information and the recommendation of a qualified healthcare professional.

10. When Not to Use

Do not use the product in patients with a known serious hypersensitivity to its active ingredients or other components where the approved product information specifies a contraindication.

Before administration:

• Review previous reactions to cefepime and other cephalosporins.

• Assess any history of serious allergy to penicillins or other beta-lactam antibiotics.

• Consider renal function and relevant patient-specific risks.

• Check the approved contraindications for both ingredients and the finished formulation.

A penicillin allergy does not automatically contraindicate every cephalosporin. The nature and severity of previous reactions should be assessed by a qualified healthcare professional.

11. Drug / Product Interactions

Potential interactions should be reviewed against the approved prescribing information and the patient’s current medication list.

Relevant considerations may include:

• Aminoglycosides: Concurrent use may warrant renal-function monitoring.

• Medicines affecting renal function: Review concurrent treatment where impaired drug clearance or increased toxicity is a concern.

• Anticoagulants: Additional monitoring may be appropriate where supported by the specific medicines and clinical circumstances.

• Other antibiotics: Combination treatment should be based on clinical need and appropriate prescribing guidance.

These are considerations for professional review, not a claim that every interaction applies to this product. Consult the full prescribing information before use.

12. Safety Advice

• Use only under appropriate medical supervision.

• Verify the product identity, strength and individual ingredient quantities.

• Review the patient’s allergy history before administration.

• Assess renal function and adjust dosage when required by the approved information.

• Follow product-specific preparation, compatibility and administration instructions.

• Monitor for allergic reactions, severe diarrhoea and neurological changes as clinically appropriate.

• Use antibiotics only for appropriate bacterial indications and follow antimicrobial stewardship principles.

Pregnancy, breastfeeding and paediatric use should be assessed according to the approved product information and individual clinical circumstances.

13. General Instructions

• Verify the product name, composition, strength, batch number and expiry date.

• Inspect the vial and container closure for damage.

• Follow the approved instructions for reconstitution and administration.

• Maintain appropriate aseptic handling practices.

• Do not use damaged containers or products that fail applicable quality checks.

• Confirm compatibility before mixing with other medicines.

• Follow product-specific instructions for use and storage after reconstitution.

• Dispose of unused medicine and clinical waste according to applicable procedures.

Do not assume a universal diluent, preparation volume, administration method or post-reconstitution stability period.

14. Special Dietary / Lifestyle Tips

No universal dietary restriction can be established for this injectable combination from the supplied product details.

• Follow the treatment plan provided by the healthcare professional.

• Complete treatment according to the prescribed instructions.

• Do not share antibiotics with other people.

• Report persistent diarrhoea, rash, confusion or other concerning symptoms promptly.

• Follow individual fluid-intake advice if kidney disease or another medical condition requires restrictions.

Dietary and lifestyle guidance should be tailored to the patient’s overall medical condition.

15. Comparison with Other Treatments

Cefepime and tazobactam combine a cephalosporin antibiotic with a beta-lactamase inhibitor. Their clinical role depends on the approved formulation and its documented antibacterial activity.

The combination should not be assumed to be more effective than other antibiotics in every situation. Antibiotic selection depends on the suspected or confirmed pathogen, susceptibility results, infection site, patient factors and local treatment guidance.

16. Precautions & Warnings

• Hypersensitivity: Review previous reactions to cephalosporins, penicillins and other beta-lactam antibiotics.

• Renal impairment: Renal-function assessment and dosage adjustment may be necessary.

• Neurological effects: Cefepime-associated neurological toxicity is an important consideration, particularly in patients with impaired renal function.

• Antibiotic-associated diarrhoea: Severe or persistent diarrhoea requires medical assessment.

• Laboratory monitoring: Blood counts, renal function or liver function may require monitoring depending on the patient’s condition and approved product information.

• Antimicrobial resistance: Avoid inappropriate use and follow local antibiotic stewardship guidance.

• Special populations: Pregnancy, breastfeeding and paediatric use require assessment against the approved product information.

The full warnings for the exact combination must be verified before publication.

17. Can I Use It With Other Medicines?

Concurrent use depends on the exact formulation, the patient’s medical condition and the other medicines being taken.

Inform the healthcare professional about:

• All prescription and non-prescription medicines.

• Other antibiotics.

• Aminoglycosides and medicines that may affect renal function.

• Anticoagulants and other medicines requiring monitoring.

• Vitamins and supplements.

Physical compatibility is different from systemic drug interactions. Do not mix this product with another medicine in a syringe, infusion container or administration line unless compatibility has been confirmed in the approved instructions.

18. Storage

Store according to the manufacturer’s approved product labelling. Refer to the product packaging or package insert for the applicable storage conditions.

Storage requirements before reconstitution may differ from those after preparation. Temperature limits, protection requirements and the permitted period of use after reconstitution must be confirmed from the documentation for this exact formulation.

19. Frequently Asked Questions (FAQs)

1. What is Cefepime HCl and Tazobactam Injection used for?

It is a combination antibacterial product intended for selected bacterial infections when supported by the approved prescribing information. The exact indications must be confirmed for this formulation.

2. Which active ingredients does this product contain?

The supplied product name identifies cefepime HCl and tazobactam. The individual quantities for each presentation should be verified against the approved product specification.

3. What strengths are listed for this product?

The supplied strengths are 281.25 Mg, 562.5 Mg, 1.125 Gm. and 2.25 Gm. Confirm how these strengths correspond to the individual ingredients and available presentations before publication.

4. How is this dry powder injection prepared?

A qualified healthcare professional must prepare the product according to its approved instructions. The diluent, preparation volume and administration method must be confirmed from the product-specific documentation.

5. Can patients with a penicillin allergy receive this combination?

An appropriate allergy assessment is necessary. A healthcare professional should review the previous reaction, potential cross-reactivity and product-specific contraindications.

6. What precautions are important during treatment?

Important considerations include allergy history, renal function, appropriate dosage, neurological symptoms and severe or persistent diarrhoea.

7. How should the product be stored?

Follow the manufacturer’s approved labelling. Storage conditions before and after reconstitution must be confirmed from the product-specific documentation.

8. Is this product available for pharmaceutical export?

Kelar Pharmachem India is a pharmaceutical sourcing and export company. Availability, packing configurations, supporting documentation and destination-market requirements should be confirmed with the company.

This information is intended for pharmaceutical product reference and does not replace approved prescribing information or professional medical advice.